CN101001646B - 稳定化的合成免疫原投递系统 - Google Patents

稳定化的合成免疫原投递系统 Download PDF

Info

Publication number
CN101001646B
CN101001646B CN03804021.2A CN03840212A CN101001646B CN 101001646 B CN101001646 B CN 101001646B CN 03840212 A CN03840212 A CN 03840212A CN 101001646 B CN101001646 B CN 101001646B
Authority
CN
China
Prior art keywords
group
water
peptide
immunostimulating complex
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN03804021.2A
Other languages
English (en)
Chinese (zh)
Inventor
肯尼士·K·沙寇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Biomedical Inc
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Application granted granted Critical
Publication of CN101001646B publication Critical patent/CN101001646B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN03804021.2A 2002-02-14 2003-02-14 稳定化的合成免疫原投递系统 Expired - Lifetime CN101001646B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/076,674 US8088388B2 (en) 2002-02-14 2002-02-14 Stabilized synthetic immunogen delivery system
US10/076,674 2002-02-14
US10/355,161 2003-01-31
PCT/US2003/004711 WO2003068169A2 (en) 2002-02-14 2003-02-14 Stabilized synthetic immunogen delivery system
US10/355,161 US8084015B2 (en) 2002-02-14 2003-05-21 Stabilized synthetic immunogen delivery system

Publications (1)

Publication Number Publication Date
CN101001646B true CN101001646B (zh) 2014-01-01

Family

ID=33422414

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA038040212A Granted CN101001646A (zh) 2002-02-14 2003-02-14 稳定化的合成免疫原投递系统
CN03804021.2A Expired - Lifetime CN101001646B (zh) 2002-02-14 2003-02-14 稳定化的合成免疫原投递系统

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNA038040212A Granted CN101001646A (zh) 2002-02-14 2003-02-14 稳定化的合成免疫原投递系统

Country Status (14)

Country Link
US (2) US8088388B2 (US08084015-20111227-C00002.png)
EP (1) EP1572074B1 (US08084015-20111227-C00002.png)
JP (2) JP5156170B2 (US08084015-20111227-C00002.png)
CN (2) CN101001646A (US08084015-20111227-C00002.png)
AT (1) ATE540697T1 (US08084015-20111227-C00002.png)
AU (1) AU2003213091C1 (US08084015-20111227-C00002.png)
BR (1) BRPI0307724B8 (US08084015-20111227-C00002.png)
CA (1) CA2475102C (US08084015-20111227-C00002.png)
DK (1) DK1572074T3 (US08084015-20111227-C00002.png)
ES (1) ES2383172T3 (US08084015-20111227-C00002.png)
HK (1) HK1085652A1 (US08084015-20111227-C00002.png)
MX (1) MXPA04007935A (US08084015-20111227-C00002.png)
TW (1) TWI359025B (US08084015-20111227-C00002.png)
WO (1) WO2003068169A2 (US08084015-20111227-C00002.png)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US8668737B2 (en) 1997-10-10 2014-03-11 Senorx, Inc. Tissue marking implant
US7637948B2 (en) 1997-10-10 2009-12-29 Senorx, Inc. Tissue marking implant
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6725083B1 (en) 1999-02-02 2004-04-20 Senorx, Inc. Tissue site markers for in VIVO imaging
US6862470B2 (en) 1999-02-02 2005-03-01 Senorx, Inc. Cavity-filling biopsy site markers
US7983734B2 (en) 2003-05-23 2011-07-19 Senorx, Inc. Fibrous marker and intracorporeal delivery thereof
US7651505B2 (en) 2002-06-17 2010-01-26 Senorx, Inc. Plugged tip delivery for marker placement
US9820824B2 (en) 1999-02-02 2017-11-21 Senorx, Inc. Deployment of polysaccharide markers for treating a site within a patent
US20090216118A1 (en) 2007-07-26 2009-08-27 Senorx, Inc. Polysaccharide markers
US8498693B2 (en) 1999-02-02 2013-07-30 Senorx, Inc. Intracorporeal marker and marker delivery device
US8361082B2 (en) 1999-02-02 2013-01-29 Senorx, Inc. Marker delivery device with releasable plug
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6575991B1 (en) 1999-06-17 2003-06-10 Inrad, Inc. Apparatus for the percutaneous marking of a lesion
EP2319449B1 (en) 2000-11-20 2016-03-09 Senorx, Inc. Tissue site markers for in vivo imaging
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002361468A1 (en) * 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
US7615227B2 (en) * 2001-12-20 2009-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce angiogenesis
US8466116B2 (en) 2001-12-20 2013-06-18 The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
JP2006505523A (ja) * 2002-08-12 2006-02-16 ダイナバックス テクノロジーズ コーポレイション 免疫調節組成物、その製造方法および使用方法
US8263091B2 (en) 2002-09-18 2012-09-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
US20060036158A1 (en) 2003-11-17 2006-02-16 Inrad, Inc. Self-contained, self-piercing, side-expelling marking apparatus
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
US7877133B2 (en) 2003-05-23 2011-01-25 Senorx, Inc. Marker or filler forming fluid
US7456306B2 (en) * 2003-07-28 2008-11-25 Mallinckrodt Inc Stearate composition and method of production thereof
US20050273002A1 (en) 2004-06-04 2005-12-08 Goosen Ryan L Multi-mode imaging marker
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US10357328B2 (en) 2005-04-20 2019-07-23 Bard Peripheral Vascular, Inc. and Bard Shannon Limited Marking device with retractable cannula
CA2562580C (en) 2005-10-07 2014-04-29 Inrad, Inc. Drug-eluting tissue marker
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
WO2008105773A2 (en) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
JP5630998B2 (ja) 2006-05-15 2014-11-26 マサチューセッツ インスティテュート オブ テクノロジー 機能的粒子のためのポリマー
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
EP2079385B1 (en) 2006-10-23 2013-11-20 C.R.Bard, Inc. Breast marker
US9579077B2 (en) 2006-12-12 2017-02-28 C.R. Bard, Inc. Multiple imaging mode tissue marker
US8401622B2 (en) 2006-12-18 2013-03-19 C. R. Bard, Inc. Biopsy marker with in situ-generated imaging properties
JP2008174490A (ja) * 2007-01-18 2008-07-31 Nitto Denko Corp 抗原性ペプチドを主成分とする薬剤
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124639A2 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
JP2008308474A (ja) * 2007-06-18 2008-12-25 Nitto Denko Corp 抗原ペプチド製剤の調製方法
MX2010003642A (es) 2007-10-12 2010-08-09 Massachusetts Inst Technology Nanotecnologia de vacuna.
US8311610B2 (en) 2008-01-31 2012-11-13 C. R. Bard, Inc. Biopsy tissue marker
DE102008024470B4 (de) * 2008-05-21 2022-10-20 Faurecia Emissions Control Technologies, Germany Gmbh Verfahren zum Regenerieren eines Abgasreinigungsfilters sowie Verdampfer
AU2009263759B2 (en) 2008-06-27 2013-06-06 Zoetis Services Llc Novel adjuvant compositions
US20090005320A1 (en) * 2008-09-02 2009-01-01 Bruce Kneller Compositions comprising amino acid bicarbonate and methods of use thereof
US9327061B2 (en) 2008-09-23 2016-05-03 Senorx, Inc. Porous bioabsorbable implant
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
PE20142330A1 (es) 2008-12-09 2015-01-14 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige
US8670818B2 (en) 2008-12-30 2014-03-11 C. R. Bard, Inc. Marker delivery device for tissue marker placement
WO2010138192A2 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Nanocarriers possessing components with different rates of release
CN103936841B (zh) * 2009-06-04 2016-01-20 中牧实业股份有限公司 一种动物用肽疫苗及其制备
CN103002919B (zh) * 2010-02-04 2015-03-25 得克萨斯系统大学评议会 纳米聚合物对免疫调节剂的肿瘤靶向递送
JP5835741B2 (ja) 2010-02-26 2015-12-24 国立大学法人 長崎大学 抗原または薬物送達複合体
EA030620B1 (ru) 2010-05-26 2018-09-28 Селекта Байосайенсиз, Инк. Композиции для выработки иммунного ответа к наборам поверхностных антигенов, содержащие синтетические наноносители, и их применение
US9932372B2 (en) * 2010-07-08 2018-04-03 United Biomedical, Inc. Designer peptide-based PCV2 vaccine
US20120070459A1 (en) * 2010-09-22 2012-03-22 Goovaerts Daniel G E Method for keeping a foot-and-mouth disease vaccine available for emergency vaccination
CN102010461B (zh) * 2010-10-11 2014-02-12 华南理工大学 一种alpha螺旋状阳离子多肽分子及其制法和应用
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
JP5930146B2 (ja) * 2011-03-28 2016-06-08 国立研究開発法人物質・材料研究機構 免疫刺激オリゴヌクレオチドおよび前記免疫刺激オリゴヌクレオチドを含む治療剤
US10933129B2 (en) 2011-07-29 2021-03-02 Selecta Biosciences, Inc. Methods for administering synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte responses
JP6178336B2 (ja) * 2011-12-30 2017-08-09 ユナイテッド・バイオメディカル・インコーポレーテッドＵｎｉｔｅｄ Ｂｉｏｍｅｄｉｃａｌ Ｉｎｃｏｒｐｏｒａｔｅｄ ブタ生殖器呼吸器症候群（ｐｒｒｓ）の有効な制御のための合成ペプチドベースのマーカーワクチン及び診断システム
CN104244973B (zh) * 2012-11-16 2017-10-20 美国联合生物医学公司 针对口蹄疫(fmd)的基于合成肽的紧急疫苗
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
US10894963B2 (en) 2013-07-25 2021-01-19 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
KR20200039025A (ko) * 2013-09-19 2020-04-14 조에티스 서비시즈 엘엘씨 유성 아쥬반트
USD715442S1 (en) 2013-09-24 2014-10-14 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716451S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD715942S1 (en) 2013-09-24 2014-10-21 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
USD716450S1 (en) 2013-09-24 2014-10-28 C. R. Bard, Inc. Tissue marker for intracorporeal site identification
CN103848902B (zh) * 2014-03-07 2016-07-13 中牧实业股份有限公司 一种合成肽疫苗及其制备方法
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
AU2014401765A1 (en) * 2014-07-25 2017-01-12 United Biomedical, Inc. Immunogenic LHRH composition and use thereof in pigs
EP3220895B1 (en) 2014-11-21 2022-08-31 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US9502964B2 (en) * 2014-12-16 2016-11-22 Intel Corporation Systems and methods for skewing DC/DC converter phases to mitigate spurs
CN114699518A (zh) 2015-01-16 2022-07-05 硕腾服务有限责任公司 口蹄疫疫苗
KR20230141834A (ko) * 2015-02-09 2023-10-10 슬링샷 바이오사이언시즈 인코포레이티드 튜닝가능한 광 특성을 갖는 하이드로겔 입자 및 이를 사용하기 위한 방법
HUE054422T2 (hu) * 2015-07-20 2021-09-28 Zoetis Services Llc Liposzómás adjuváns készítmények
WO2017043490A1 (ja) * 2015-09-07 2017-03-16 協和発酵バイオ株式会社 自然免疫誘導効果が増強した二重鎖リボ核酸
CN109152829A (zh) 2016-06-02 2019-01-04 硕腾服务有限责任公司 针对传染性支气管炎的疫苗
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
CN107703294B (zh) * 2017-10-12 2019-06-04 华派生物工程集团有限公司 一种用于检测鸡血清中cLHRH抗体效价的ELISA方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025060A1 (en) * 1993-04-27 1994-11-10 Ladd Anna E Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
US5702716A (en) * 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5135751A (en) * 1988-11-16 1992-08-04 Mediventures Incorporated Composition for reducing postsurgical adhesions
US5126141A (en) * 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
GB8921470D0 (en) 1989-09-22 1989-11-08 Peptide Technology Ltd Vaccines
ES2081384T3 (es) * 1990-04-25 1996-03-01 Hoechst Ag Preparado farmaceutico que contiene complejos de polielectrolitos en forma de microparticulas y por lo menos una sustancia activa.
US5149543A (en) * 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
WO1993001286A2 (en) 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Localized oligonucleotide therapy
US5759551A (en) * 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
US5562909A (en) * 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US6194388B1 (en) * 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5656611A (en) * 1994-11-18 1997-08-12 Supratek Pharma Inc. Polynucleotide compositions
US6902743B1 (en) * 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US6042820A (en) * 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US20040202680A1 (en) * 1997-01-30 2004-10-14 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU760034B2 (en) * 1997-08-29 2003-05-08 Corixa Corporation Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
WO1999024061A1 (en) * 1997-11-07 1999-05-20 Chiron Corporation Method for producing igf-1 sustained-release formulations
BR9909915A (pt) 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
BR9911388A (pt) 1998-06-20 2001-03-20 United Biomedical Inc Imunógeno de somatostatina sintético para promoção de crescimento em animais de fazenda
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US6107021A (en) * 1998-06-20 2000-08-22 United Biomedical, Inc. Synthetic peptide vaccines for foot-and-mouth disease
US6025468A (en) * 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
TWI227241B (en) 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
AU2875700A (en) * 1999-02-26 2000-09-14 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
DE60100814T2 (de) * 2000-06-08 2004-07-01 Intercell Biomedizinische Forschungs- Und Entwicklungs Gmbh Immunstimulierende oligodeoxynukleotide
EP1296714B1 (en) * 2000-06-22 2009-08-26 University Of Iowa Research Foundation Combination of CpG and antibodies directed against CD19,CD20, CD22 or CD40 for the treatment or prevention of cancer.
WO2002053141A2 (en) * 2000-12-14 2002-07-11 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US6780969B2 (en) * 2000-12-22 2004-08-24 United Biomedical, Inc. Synthetic peptide composition as immunogens for prevention of urinary tract infection
US20040185055A1 (en) * 2001-03-19 2004-09-23 Glenn Gregory M Transcutaneous immunostimulation
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
UA84024C2 (ru) * 2003-07-24 2008-09-10 Мериал Лимитед Новые вакцинные композиции, которые содержат эмульсию типа "масло в воде"

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994025060A1 (en) * 1993-04-27 1994-11-10 Ladd Anna E Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines
WO2001022972A2 (en) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Immunostimulatory nucleic acids

Also Published As

Publication number Publication date
EP1572074A4 (en) 2008-04-30
ES2383172T3 (es) 2012-06-18
JP5237997B2 (ja) 2013-07-17
BRPI0307724B8 (pt) 2021-05-25
DK1572074T3 (da) 2012-05-07
BRPI0307724B1 (pt) 2019-06-18
CN101001646A (zh) 2007-07-18
WO2003068169A2 (en) 2003-08-21
JP2010265291A (ja) 2010-11-25
TWI359025B (en) 2012-03-01
US20030165478A1 (en) 2003-09-04
HK1085652A1 (en) 2006-09-01
WO2003068169A3 (en) 2007-03-15
JP2005530690A (ja) 2005-10-13
JP5156170B2 (ja) 2013-03-06
BR0307724A (pt) 2007-04-27
EP1572074B1 (en) 2012-01-11
ATE540697T1 (de) 2012-01-15
AU2003213091C1 (en) 2009-01-08
TW200307557A (en) 2003-12-16
MXPA04007935A (es) 2005-06-08
US8088388B2 (en) 2012-01-03
AU2003213091B2 (en) 2008-06-05
CA2475102A1 (en) 2003-08-21
US8084015B2 (en) 2011-12-27
AU2003213091A1 (en) 2003-09-04
EP1572074A2 (en) 2005-09-14
US20040009897A1 (en) 2004-01-15
CA2475102C (en) 2013-04-23

Similar Documents

Publication Publication Date Title
CN101001646B (zh) 稳定化的合成免疫原投递系统
Azmi et al. Recent progress in adjuvant discovery for peptide-based subunit vaccines
Wilson-Welder et al. Vaccine adjuvants: current challenges and future approaches
Stills Polyclonal antibody production
EP0724432B1 (en) Methods and compositions for microencapsulation of antigens for use as vaccines
Moyle et al. Mucosal immunisation: adjuvants and delivery systems
US20120014991A1 (en) Novel, non-antigenic, mucosal adjuvant formulation which modulates the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
Coeshott et al. Pluronic® F127-based systemic vaccine delivery systems
Gerdts et al. Carrier molecules for use in veterinary vaccines
Zhang et al. A comparative study of the antigen‐specific immune response induced by co‐delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles
US20070116719A1 (en) Vaccine delivery
US20020119162A1 (en) Synthetic vaccine agents
O’Hagan et al. Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen
US20060002960A1 (en) GM1 binding deficient exotoxins for use as immunoadjuvants
EP2683388A2 (en) Vaccine formulation of mannose coated peptide particles
Wilson Evaluation of the immune response to a tetanus toxoid vaccine using a novel biodegradable polymer adjuvant
JP4217418B2 (ja) キトサン誘導性免疫強化
Wilson-welder In vitro and in vivo evaluation of novel biodegradable polymer adjuvants for vaccine delivery
Kirby Formulation and characterisation of an effective particulate delivery vehicle for the novel sub-unit vaccine antigen, Ag85B-ESAT-6

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20140101